New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Jaypirca, Eli Lilly’s treatment for relapsed or refractory mantle cell lymphoma.
You may also be interested in...
Applications from drug companies should also include a commercial proposal, says Pharmac.
Health technology assessment institute NICE is scheduled to appraise Eisai/Biogen’s lecanemab and Eli Lilly’s donanemab next year.
While things are starting to look up for the commercial clinical trial ecosystem in the UK, more progress is needed to improve industry’s confidence in the country as a destination for research, especially revenue-generating Phase III trials.